Sanofi's chief executive, a French national, has been in the job just over one year and is under pressure to show progress in countering the effects of rising competition and US drug pricing pressures on the diabetes portion of the business, where sales fell 4.5% to €1.73bn ($1.99bn) in the first quarter of this year - a slide that the company predicted in 2015 before reporting a 6.8% drop in diabetes sales for 2015. Sanofi expects sales for the franchise to sink 4% to 8% annually through 2018.
So it's perhaps not surprising that Brandicourt's latest organizational revamp, announced May 23 and which builds on a restructuring unveiled...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
